Background. The impact of adjuvant chemotherapy and chemo-radiation therapy in the treatment of resectable gastric cancer remains varied. We sought to define the clinical impact of lymph node ratio on the relative benefit of adjuvant chemotherapy or chemo-radiation therapy among patients having undergone curative-intent resection for gastric cancer. Methods. Using the multi-institutional US Gastric Cancer Collaborative database, 719 patients with gastric adenocarcinoma who underwent curative-intent resection between 2000 and 2013 were identified. Patients with metastasis or an R2 margin were excluded. The impact of lymph node ratio on overall survival among patients who received chemotherapy or chemo-radiation therapy was evaluated. Results. Median patient age was 65 years, and the majority of patients were male (56.2%). The majority of patients underwent either subtotal (40.6%) or total gastrectomy (41.0%), with the remainder undergoing distal gastrectomy or wedge resection (18.4%). On pathology, median tumor size was 4 cm; most patients had a T3 (33.0%) or T4 (27.9%) lesion with lymph node metastasis (59.7%). Margin status was R0 in 92.5% of patients. A total of 325 (45.2%) patients underwent resection alone, 253 (35.2%) patients received 5-FU or capecitabine-based chemo-radiation therapy, whereas the remaining 141 (19.6%) received chemotherapy. Median overall survival was 40.9 months, and 5-year overall survival was 40.3%. According to lymph node ratio categories, 5-year overall survival for patients with a lymph node ratio of 0, 0.01-0.10, >0.10-0.25, >0.25 were 54.1%, 53.1 %, 49.1 % and 19.8 %, respectively. Factors associated with worse overall survival included involvement of the gastroesophageal junction (hazard ratio 1.8), T-stage (3-4: hazard ratio 2.1), lymphovascular invasion (hazard ratio 1.4), and lymph node ratio (>0.25: hazard ratio 2.3; all P < .05). In contrast, receipt of adjuvant chemoradiation therapy was associated with an improved overall survival in the multivariable model (versus resection alone: hazard ratio 0.40; versus chemotherapy: hazard ratio 0.45, both P < .001). The benefit of chemo-radiation therapy for resected gastric cancer was noted only among patients with lymph node ratio >0.25 (versus resection alone: hazard ratio R 0.34; versus chemotherapy: hazard ratio 0.45, both P < .001). In contrast, there was no noted overall survival benefit of chemotherapy or chemo-radiation therapy among patients with lymph node ratio #0.25 (all P > .05). Conclusion. Adjuvant chemotherapy or chemo-radiation therapy was utilized in more than one-half of patients undergoing curative-intent resection for gastric cancer. Lymph node ratio may be a useful tool to select
patients for adjuvant chemo-radiation therapy, because the benefit of chemo-radiation therapy was isolated to patients with greater degrees of lymphatic spread (ie, lymph node ratio >0. 25 GASTRIC CANCER is the fifth most common gastrointestinal cancer and the third leading cause of cancer death worldwide. 1 The American Cancer Society estimates that in 2016 there will be approximately 26,370 cases of gastric cancer resulting in nearly 11,000 deaths in the United States. 2 While complete operative resection with regional lymph node (LN) dissection remains the mainstay of cure for patients with gastric cancer, the outcome of patients with advanced disease is poor, with 5-year survival ranging from 5% to 83% depending on the stage of disease. [3] [4] [5] [6] There are discrepancies in the survival outcomes between the Eastern and Western studies, with survivals of 60% to 70% in Japanese trials compared with 30% to 40% in Western trials. 7 Previous studies reported a high incidence of locoregional or distant recurrence after operative resection of gastric cancer, suggesting the need for additional therapeutic modalities after curative gastrectomy. [8] [9] [10] [11] [12] [13] While the efficacy and safety of adjuvant chemotherapy (CTx) or chemoradiation (cXRT) therapy for gastric cancer have been studied, results have varied. 3, 14 Several randomized clinical trials (RCTs) reported improved recurrence-free and overall survival among patients who received adjuvant cXRT over adjuvant CTx or resection only. [15] [16] [17] [18] In one trial, Park et al 19 suggested that adjuvant cXRTand CTx were equally beneficial in preventing relapse of gastric cancer. Of note, in a subsequent subset analyses, Kim et al 20 demonstrated that the benefit of adjuvant cXRT for gastric cancer resected with a D2 resection over CTx was most pronounced among patients having a greater degree of lymphatic spread. As such, it is important to identify patients at high risk for recurrence, as well as to assess those who most benefit from adjuvant therapy. In addition to the TNM staging system, lymph node ratio (LNR) has been proposed as a promising tool to evaluate prognosis among patients with gastric cancer. [21] [22] [23] [24] [25] Given this concept of the importance of the LNR, we sought to evaluate the clinical impact of LNR on the relative benefit of adjuvant CTx or cXRT among patients undergoing curative intent operative resection for gastric cancer using a large, multicenter, national collaborative database. Specifically, the objective of the current study was to define the relation between LNR and overall survival (OS) using propensity-matched analysis of patients undergoing curative intent resection of gastric cancer and adjuvant CTx or cXRT.
METHODS
Patient selection. Patients who underwent curative resection for gastric cancer between January 1, 2000 and June, 30 2013 were identified from the US Gastric Cancer Collaborative (Johns Hopkins Hospital, Baltimore, MD; Emory University, Atlanta GA; Stanford University, Palo Alto, CA; Washington University, St. Louis, MO; Wake Forest University, Winston-Salem, NC; University of Wisconsin, Madison, WI; and The Ohio State University, Columbus, OH). The institutional review boards at each participating institution approved the study. Only patients who underwent resection with curative-intent were included; patients with metastatic disease and patients with macroscopically positive (R2) margins were excluded. Patients who died or were lost to follow-up within 30 days after operation, and those patients who had missing data on lymph node status were not included ( Supplementary Fig 1) .
We collected standard demographic and clinicopathologic data, including age, sex, race, body mass index, the physical status classification system of the American Society of Anesthesiologists, tumor size, tumor location, Lauren classification, histologic grade, depth of invasion, number of LNs harvested, number of metastatic LNs identified, final stage according to the American Joint Committee on Cancer (AJCC), and presence or absence of lymphovascular invasion (LVI) and perineural invasion. Treatment and operative details included type and extent of resection (wedge resection, distal gastrectomy, subtotal gastrectomy, or total gastrectomy), and estimated blood loss. 26, 27 to be more comparable with previous studies and categorized further into LNR #0.25 and LNR >0.25 after sensitivity analyses. 20, 23, [26] [27] [28] Perioperative details including information on CTx and cXRT were collected. Vital status and date of death or last follow-up also were collected.
Statistical analysis. Continuous variables were described as medians with interquartile range (IQR) and categorical variables as frequencies with percentages. Univariable comparisons for continuous variables were assessed using the Kruskal-Wallis test, while categorical variables were assessed using the v 2 or the Fisher exact test, as appropriate. Univariable and multivariable logistic regression analysis was performed to determine associations of covariates with receipt of adjuvant therapy. Variables that were statistically significant with a P value < .10 in univariable analyses were assessed in a multivariable model. OS was estimated using the Kaplan-Meier method; unadjusted differences in OS were assessed using the log-rank test. The association of relevant clinicopathologic variables with OS was assessed using a Cox proportional hazards model. To account for possible confounding variables, multivariable Cox proportional hazards regression analyses and propensity score methods were utilized. 29 Multiple imputation was performed in the multivariable analysis for covariates that were missing at <20%. Statistical analyses were performed with STATA version 14.0 (StataCorp, College Station, TX), and R version 3.0.3 (http://www.r-project. org); all tests were 2-sided.
RESULTS
Demographic and clinicopathologic characteristics. A total of 719 patients underwent resection of gastric cancer and met the inclusion criteria. The demographic and clinical characteristics of the study cohort are presented in Table I . Median patient age was 65.2 years (IQR: 56.2, 73.8), and most patients were white (n = 444, 61.8%) and male (n = 404, 56.2%). At the time of resection, the majority of patients underwent either a subtotal (n = 292, 40.6%) or total gastrectomy (n = 295, 41.0%), with the remainder undergoing a distal gastrectomy or wedge resection (n = 132, 18.4%). The majority of patients underwent a D2/3 lymphadenectomy (62.3%). On pathology, median tumor size was 4.0 cm (IQR: 2.2, 6.6); the majority of tumors were AJCC T3 (n = 232, 33.0%) or T4 (n = 196, 27.9%); approximately two-thirds of lesions (n = 478, 69.2%) were moderately to poorly differentiated tumors. A median number of 17 (IQR: 11-25) LNs were harvested. LN metastasis was found in 59.7% (n = 429) of patients, and a median number of 2 LN (IQR: 0, 7) were involved. According to AJCC 7th edition, approximately one-third of patients were N1 (n = 124, 17.3%) or N2 (n = 125, 17.4%) diseases, while one-fourth of patients were N3a (n = 126, 17.5%) or N3b (n = 54, 7.5%) diseases. On operative pathology, most patients (n = 662, 92.5%) had an R0 margin. Of note, while some demographic factors such as age and race differed between patients who underwent a D0/D1 and D2D3 resection, most clinicopathologic and tumor characteristics were comparable (Supplementary Table) .
Factors associated with receipt of adjuvant therapy. Postoperatively, 394 (54.8%) patients received adjuvant therapy (CTx: n = 141, 19.6% vs cXRT: n = 253, 35.2%), whereas 325 (45.2%) patients underwent resection only. Among those 330 patients who were available for the data on the type of adjuvant chemotherapy, the majority of patients received 5-FU-based chemotherapy (n = 191, 57.9%) or capecitabine-based chemotherapy (n = 119, 36.1%); a small subset of patients received both 5-FU and capecitabine-based regimen (n = 14, 4.2%) or other regimens (n = 6, 1.8%). On univariable analysis, factors associated with an increased likelihood to receive adjuvant therapy included tumor size, histologic grade, T stage, R1 margin, presence of LVI, perineural invasion, and the extent of lymphadenectomy as well as LNR >0.25 (Table II) . After controlling for competing risk factors on multivariable analysis, tumor size (OR 1.07, 95% CI, 1.01-1.14), moderateto-poor grade (OR 1.53, 95% CI, 1.05-2.23), T3/ T4 disease (OR 1.83, 95% CI, 1.20-2.78), and the presence of LVI (OR 1.55, 95% CI, 1.04-2.32) remained associated with an increased likelihood of receiving adjuvant therapy (all P < .05). Similarly, patients who underwent D2/D3 lymphadenectomy (OR 2.45, 95% CI, 1.71-3.51) and had a LNR >0.25 (OR 2.42, 95% CI, 1.60-3.66) were associated with an increased odds of receiving adjuvant therapy (both P < .001). In contrast, elderly patients (>65 years) were less likely to receive adjuvant therapy (OR 0.37, 95% CI, 0.27-0.53; P < .001).
Overall survival after resection for gastric cancer. Median OS was 40.9 months (95% CI, 33.9-49.5) with 1-, 3-, and 5-year OS of 78.8%, 52.5%, and 40.3%, respectively. According to LNR Fig 2) . On multivariable analysis, involvement of the gastroesophageal junction (HR 1.79, 95% CI, 1.19-2.70; P = .005), T3/T4 diseases (HR 2.08, 95% CI, 1.54-2.80; P < .001), a LNR (>0.25: HR 2.33, 95% CI, 1.79-3.03; P < .001), and the presence of LVI (HR 1.4, 95% CI, 1.09-1.79; P = .008) were associated with worse OS (Table  III) . After controlling for these factors, adjuvant cXRT (versus resetion alone: HR 0.40, 95% CI, 0.30-0.53; versus CTx: HR 0.45, 95% CI, 0.33-0.62; both P < .001) remained associated with a decreased risk of death. The effect of adjuvant cXRT compared with adjuvant CTx or resection alone on OS was most pronounced among patients with greater degrees of LN spread (ie, LNR >0.25) (Fig 1) . In contrast, cXRT did not confer an OS benefit among patients who had a LNR #0.25 or patients who had N0 disease (both P > .05). When stratified by the extent of lymphadenectomy, among patients undergoing an extended (D2/D3) lymphadenectomy, the benefit of adjuvant cXRT therapy was present only among those patients who had LNR >0.25 (Fig 2, A) . In contrast, among patients undergoing D0/D1 lymphadenectomy, the benefit of adjuvant cXRT versus CTx was noted among patients who had both low (LNR #0.25) had high (LNR >0.25) metastatic LN burden; the benefit of adjuvant cXRT versus resection alone was limited to patients with LNR >0.25 (Fig 2, B) . After excluding patients who received any form of preoperative chemotherapy, the effect of adjuvant therapy was the same. Specifically, the benefit of cXRT for resected gastric cancer was noted only among patients with LNR >0.25 (versus resection alone: HR 0.34, P < .001; versus CTx: HR 0.48, P = .001). In contrast, there was no OS benefit of CTx or cXRT among patients with LNR #0.25 (all P > .05). Propensity-matched analyses then were undertaken to minimize confounding by indication and to create more balanced cohorts of patients who received adjuvant cXRT versus CTx. After propensity-matching for age, sex, tumor size, tumor grade, T stage, operative margin status, type of operation, and presence/absence of LVI, the propensity-matched cohort included 241 patients who received adjuvant cXRT therapy versus 141 patients who had adjuvant CTx. On propensity-matched analysis, the benefit of adjuvant cXRT over adjuvant CTx therapy alone remained for patients who had undergone D2/D3 lymphadenectomy and had a LNR >0.25 (Fig 3) .
DISCUSSION
Gastric cancer is the third leading cause of cancer deaths worldwide. While resection provides the best chance at cure, recurrence is common, and therefore, long-term cure can be difficult to achieve. 1, 8, 30 Recurrence can range widely from 5% to 90% depending on the stage of the disease, and patterns of recurrence can be varied (eg, locoregional, hematogenous, peritoneal). [8] [9] [10] [11] Given the high incidence of recurrence, adjuvant chemotherapy and/or radiation therapy has been considered to improve patient long-term clinical outcomes. 12 Several studies have sought to evaluate the efficacy and safety of adjuvant chemotherapy (CTx) or chemoradiation therapy (cXRT) among patients with gastric cancer. 12, [16] [17] [18] [19] [31] [32] [33] [34] [35] The results of these studies have been controversial as well as limited by small sample size and lack of a cohort receiving contemporary chemotherapy regimens. The current study is important, because it reports the outcomes of adjuvant CTx/cXRT among a contemporary cohort of patients with gastric cancer using one of the largest, multi-institutional experiences on the operative management of gastric cancer in the United States. More importantly, using both multivariable and propensity-matched analyses, a beneficial effect of adjuvant cXRT compared with CTx or resection alone was noted for patients undergoing resection of gastric cancer. Of note, the benefit of adjuvant cXRT was most pronounced among those patients with greater degrees of LN disease (ie, LNR >0.25) who underwent extended lymphadenectomy (D2/D3).
In the present study, adjuvant therapy was utilized in more than one-half of patients undergoing curative-intent resection for gastric cancer. Receipt of adjuvant therapy was associated with certain patient and clinicopathologic factors, including extent of lymphadenectomy and a greater degree of LN spread. Of note, elderly patients (>65 years) were 60% less likely to receive adjuvant therapy. Use of adjuvant therapy after resection of gastric in the elderly population remains debated. For example, a recent metaanalysis of adjuvant therapy for gastric cancer reported no benefit of adjuvant chemotherapy among the elderly population. 36 In contrast, in a separate study by Jo et al, 37 the authors reported that adjuvant chemotherapy may confer a potential survival benefit in elderly patients with stages II or III gastric cancer after a D2 resection. These data suggest that a different strategy and risk stratification may be needed for the elderly patients that considers their functional, social, and mental conditions.
The efficacy and safety of adjuvant therapy for gastric cancer has been investigated in several RCTs. [15] [16] [17] [18] [19] 31 A large, phase III RCT of 556 patients with gastric cancer demonstrated that OS and relapse-free survival was improved among patients undergoing adjuvant cXRT versus resection alone. 17 Several other studies have reported similarly that adjuvant cXRT provided an incremental survival benefit over adjuvant CTx or resection alone. 5, [14] [15] [16] 18, 38 The present data confirmed the survival benefit of adjuvant cXRT therapy compared with resection alone, especially in those patients at greatest risk of recurrence (ie, LNR >0.25). Interestingly, in a phase III trial of 458 patients with resected gastric cancer who had a D2 dissection, the Adjuvant Chemo-radiotherapy in Stomach Tumors (ARTIST) trial noted that adjuvant cXRT did not significantly decrease recurrence or risk of death. 19, 31 Interestingly, in a subset analyses of the ARTIST trial, Park et al 19 reported that adjuvant cXRT was beneficial for patients with N1 disease and intestinal type gastric cancers. These data suggested strongly that further risk prediction was need to refine better which patients might benefit from adjuvant therapy.
Rather than stratifying patients as simply N0 versus N1 when assessing extent of nodal disease, the ratio between metastatic and examined lymph nodes (LNR) has been proposed as a better predictor of long-term outcomes after resection of gastric cancer. [20] [21] [22] [23] [24] [25] [26] 28, 39 The present study confirmed that LNR was a strong, independent prognostic indicator of tumor prognosis relative to other risk factors. Two previous studies also had reported the potential role of LNR to select patients for adjuvant cXRT after gastric operation with D2 lymphadenectomy. 20, 28 In turn, these findings were consistent with data reported by Kim et al 20 in the phase III ARTIST trial in which the survival benefit of adjuvant cXRT was most pronounced among patients with LNR >0.25. In contrast, Costa et al 28 reported an observational study that found adjuvant cXRT to benefit patients with milder degrees of LN disease (ie, LNR 0.10-0.25). The reasons for these disparate results are likely multifactorial and related to study design and patient selection. For example, unlike the study by Kim et al, the report by Costa et al was retrospective and had a smaller sample size. In the present study, we noted that the benefit of adjuvant cXRT was most pronounced among patients with a greater degree of LN disease (ie, LNR >0.25) who had undergone an extended (D2/D3) lymphadenectomy. Collectively, data from the present study as well as Kim et al suggest strongly that systemic cXRT may benefit patients differently after gastric resection. In particular, administration of adjuvant cXRT may benefit patients with resected gastric cancer in a subset of patients based on LNR and therefore, help select gastric cancer patients for adjuvant cXRT.
Several limitations should be considered when interpreting our report. While the collaboration among multiple institutions increased the generalizability of the results, this multi-institutional study design limited the ability to standardize treatment criteria including the regimen of adjuvant therapy. While the use of multivariable analyses and propensity-matching allowed us to control for measurable confounders, unmeasured/residual confounders could not be taken into account given the nonrandomized observational design. In addition, data on the number of chemotherapy cycles received, as well as any chemotherapy associated toxicity, were not available.
In conclusion, adjuvant CTx or cXRT were utilized in more than one-half of patients undergoing curative-intent resection for gastric cancer. After adjusting for varied clinicopathologic factors in the no adjuvant versus adjuvant gastric cancer cohorts using multivariable and propensitymatching, cXRT remained independently associated with a long-term survival benefit. LNR may be a useful tool to select patients for adjuvant cXRT, because the benefit of cXRT therapy was isolated to patients with greater degrees of LN disease (ie, LNR >0.25).
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